145 related articles for article (PubMed ID: 35603854)
1. Physician Dispensing Among Urology Practices and the Use of Abiraterone or Enzalutamide for Men With Advanced Prostate Cancer.
Lai LY; Kaufman SR; Oerline MK; Caram MEV; Maganty A; Hollenbeck BK; Shahinian VB
JNCI Cancer Spectr; 2022 Mar; 6(2):. PubMed ID: 35603854
[TBL] [Abstract][Full Text] [Related]
2. Adoption of Abiraterone and Enzalutamide by Urologists.
Caram MEV; Kaufman SR; Modi PK; Herrel L; Oerline M; Ross R; Skolarus TA; Hollenbeck BK; Shahinian V
Urology; 2019 Sep; 131():176-183. PubMed ID: 31136769
[TBL] [Abstract][Full Text] [Related]
3. Effects of In-office Dispensing by Single-specialty Urology Practices on Management of Advanced Prostate Cancer.
Lai LY; Kaufman SR; Oerline M; Caram MEV; Maganty A; Shahinian VB; Hollenbeck BK
Urol Pract; 2023 May; 10(3):230-235. PubMed ID: 37103497
[TBL] [Abstract][Full Text] [Related]
4. Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D.
Caram MEV; Borza T; Min HS; Griggs JJ; Miller DC; Hollenbeck BK; Mukherjee B; Skolarus TA
J Oncol Pract; 2017 Aug; 13(8):e694-e702. PubMed ID: 28628393
[TBL] [Abstract][Full Text] [Related]
5. In-office dispensing of oral targeted agents by urology practices in men with advanced prostate cancer.
Hill D; Kaufman SR; Oerline MK; Faraj K; Caram MEV; Shahinian VB; Hollenbeck BK; Maganty A
JNCI Cancer Spectr; 2023 Jul; 7(5):. PubMed ID: 37643638
[TBL] [Abstract][Full Text] [Related]
6. Promotional Payments Made to Urologists by the Pharmaceutical Industry and Prescribing Patterns for Targeted Therapies.
Hollenbeck BK; Oerline M; Kaufman SR; Caram MEV; Dusetzina SB; Ryan AM; Shahinian VB
Urology; 2021 Feb; 148():134-140. PubMed ID: 33075381
[TBL] [Abstract][Full Text] [Related]
7. Risk of Metabolic and Cardiovascular Adverse Events With Abiraterone or Enzalutamide Among Men With Advanced Prostate Cancer.
Lai LY; Oerline MK; Caram MEV; Tsao PA; Kaufman SR; Hollenbeck BK; Shahinian VB
J Natl Cancer Inst; 2022 Aug; 114(8):1127-1134. PubMed ID: 35417024
[TBL] [Abstract][Full Text] [Related]
8. Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer.
Caram MEV; Oerline MK; Dusetzina S; Herrel LA; Modi PK; Kaufman SR; Skolarus TA; Hollenbeck BK; Shahinian V
Cancer; 2020 Dec; 126(23):5050-5059. PubMed ID: 32926427
[TBL] [Abstract][Full Text] [Related]
9. Promotional Payments to Medical Oncologists and Urologists and Prescriptions for Abiraterone and Enzalutamide.
Lai LY; Oerline MK; Kaufman SR; Herrel LA; Skolarus TA; Dusetzina SB; Ellimoottil C; Shahinian VB; Hollenbeck BK; Caram MEV
Urology; 2022 Mar; 161():50-58. PubMed ID: 34861316
[TBL] [Abstract][Full Text] [Related]
10. Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
Suzuki H; Castellano D; de Bono J; Sternberg CN; Fizazi K; Tombal B; Wülfing C; Foster MC; Ozatilgan A; Geffriaud-Ricouard C; de Wit R
Jpn J Clin Oncol; 2021 Aug; 51(8):1287-1297. PubMed ID: 33738495
[TBL] [Abstract][Full Text] [Related]
11. Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 With Cognitive Function in Older Men With Metastatic Castration-Resistant Prostate Cancer.
Alibhai SMH; Breunis H; Feng G; Timilshina N; Hansen A; Warde P; Gregg R; Joshua A; Fleshner N; Tomlinson G; Emmenegger U
JAMA Netw Open; 2021 Jul; 4(7):e2114694. PubMed ID: 34213559
[TBL] [Abstract][Full Text] [Related]
12. The lack of a relationship between physician payments from drug manufacturers and Medicare claims for abiraterone and enzalutamide.
Bandari J; Ayyash OM; Turner RM; Jacobs BL; Davies BJ
Cancer; 2017 Nov; 123(22):4356-4362. PubMed ID: 28749536
[TBL] [Abstract][Full Text] [Related]
13. Time on treatment with abiraterone and enzalutamide in the Patient-overview Prostate Cancer in The National Prostate Cancer Register of Sweden.
Fallara G; Alverbratt C; Garmo H; Vikman H; Hjelm Eriksson M; Lissbrant IF; Stattin P
Acta Oncol; 2021 Dec; 60(12):1589-1596. PubMed ID: 34533422
[TBL] [Abstract][Full Text] [Related]
14. Skeletal-related events after abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer: A population-based study using the SEER-Medicare linked dataset.
Kwon DH; Paciorek A; Zhang L; Borno HT; Bucknor M; Small EJ; Aggarwal RR
Urol Oncol; 2022 Aug; 40(8):379.e17-379.e24. PubMed ID: 35750560
[TBL] [Abstract][Full Text] [Related]
15. HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies.
Khalaf DJ; Aragón IM; Annala M; Lozano R; Taavitsainen S; Lorente D; Finch DL; Romero-Laorden N; Vergidis J; Cendón Y; Oja C; Pacheco MI; Zulfiqar M; ; Gleave ME; Wyatt AW; Olmos D; Chi KN; Castro E
Ann Oncol; 2020 Sep; 31(9):1186-1197. PubMed ID: 32574722
[TBL] [Abstract][Full Text] [Related]
16. Characterizing Out-of-Pocket Payments and Financial Assistance for Patients Prescribed Abiraterone and Enzalutamide at an Academic Cancer Center Specialty Pharmacy.
Jeong AY; Schwartz EB; Roman AR; McDevitt RL; Oerline MK; Henry E; Veenstra CM; Caram MEV
JCO Oncol Pract; 2022 Feb; 18(2):e284-e292. PubMed ID: 34491783
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.
Sternberg CN; Castellano D; de Bono J; Fizazi K; Tombal B; Wülfing C; Kramer G; Eymard JC; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; de Wit R
Eur Urol; 2021 Oct; 80(4):497-506. PubMed ID: 34274136
[TBL] [Abstract][Full Text] [Related]
18. Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic prostate cancer patients.
Kulkarni AA; Rubin N; Tholkes A; Shah S; Ryan CJ; Lutsey PL; Prizment A; Rao A
ESMO Open; 2021 Oct; 6(5):100261. PubMed ID: 34509804
[TBL] [Abstract][Full Text] [Related]
19. Prescribing Patterns of Oral Antineoplastic Therapies Observed in the Treatment of Patients With Advanced Prostate Cancer Between 2012 and 2014: Results of an Oncology EMR Analysis.
Malangone-Monaco E; Foley K; Varker H; Wilson KL; McKenzie S; Ellis L
Clin Ther; 2016 Aug; 38(8):1817-24. PubMed ID: 27491282
[TBL] [Abstract][Full Text] [Related]
20. Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide.
Brown LC; Halabi S; Schonhoft JD; Yang Q; Luo J; Nanus DM; Giannakakou P; Szmulewitz RZ; Danila DC; Barnett ES; Carbone EA; Zhao JL; Healy P; Anand M; Gill A; Jendrisak A; Berry WR; Gupta S; Gregory SG; Wenstrup R; Antonarakis ES; George DJ; Scher HI; Armstrong AJ
Clin Cancer Res; 2021 Jul; 27(14):4077-4088. PubMed ID: 33820782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]